- |||||||||| Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Multimedia Health Education on Insulin Injection Skills for Patients With Type 2 Diabetes (Pubmed Central) - Mar 30, 2022
Multimedia health education may not only enhance patients' self-injection skills but also save on human resources and nursing hours. The findings of this study may provide references for healthcare providers in educating patients with diabetes regarding self-administering insulin pen injections.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Clinical, Journal: Affordability of Medication Therapy in Diabetic Patients: A Scenario-Based Assessment in Iran's Health System Context. (Pubmed Central) - Mar 26, 2022
The findings of this study may provide references for healthcare providers in educating patients with diabetes regarding self-administering insulin pen injections. Although oral medication therapies were documented to be affordable, insulin therapy, with current coverage conditions, for patients with lowest paid wages and those receiving even less is unaffordable and a major barrier to treatment; hence, policy-maker should consider targeting and more financial protection policies to improve the affordability of insulin therapies among this group of patients.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
RISK FACTORS FOR HYPOGLYCEMIA DURING THE TREATMENT OF HYPERGLYCEMIC CRISES ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1861;
Many of these factors are not addressed in consensus statement recommendations for management of hyperglycemic crises. Resumption of chronic insulin regimen following resolution of hyperglycemic crisis, a consensus statement recommendation, was found to be associated with increased odds of hypoglycemia.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Clinical, Journal: Epidemiology of hypoglycaemic episodes leading to hospitalisations in Denmark in 1998-2018. (Pubmed Central) - Mar 19, 2022
Incidence rates of hypoglycaemic episodes leading to hospitalisation are declining in Denmark, and the advent of new treatment alternatives may play a significant role in this decline. From a safety perspective, these findings are important and should be considered by clinicians when assessing treatment options for patients.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Review, Journal: Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes. (Pubmed Central) - Feb 26, 2022
A basic knowledge of the physiology, pharmacodynamic and pharmacokinetic aspects of the different basal insulins is essential to achieve treatment goals and compliance. This review addresses the principles of management with basal insulins.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Review, Journal: The Comparative Dosing and Glycemic Control of Intermediate and Long-Acting Insulins in Adult Patients With Type 1 and 2 Diabetes Mellitus. (Pubmed Central) - Feb 11, 2022
A Medline and Web of Science search was conducted in September 2021 using the following keywords and medical subjecting headings: NPH, glargine, detemir, type 1 diabetes mellitus, and type 2 diabetes mellitus...When transitioning between long-acting insulins, the doses are not always interchangeable on a 1:1 basis. Unit dose adjustments are likely if transitioning between BIs and can influence short-term parameters in the acute care setting and long-term parameters in the outpatient setting.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk, NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (clinicaltrials.gov) - Feb 11, 2022
P2/3, N=80, Active, not recruiting,
Unit dose adjustments are likely if transitioning between BIs and can influence short-term parameters in the acute care setting and long-term parameters in the outpatient setting. Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Retrospective data, Review, Journal: Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis. (Pubmed Central) - Feb 5, 2022
Compared with second-generation basal insulins, low to high certainty evidence suggested that NPH was associated with a higher risk of patients experiencing severe hypoglycemia; NPH and first-generation basal insulins were associated with a higher rate of nocturnal confirmed hypoglycemic events. For the weight gain, glargine U300 was comparable to detemir (low certainty), but degludec U100 was greater than detemir (moderate certainty).In conclusion, second-generation basal insulins maintained equivalent efficacy of glycemic control (moderate to high certainty), with differences in safety (low to high certainty) compared with NPH and first-generation basal insulins during ≥ 24 weeks of follow-up in T1D adults.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin. (Pubmed Central) - Jan 18, 2022
This retrospective, new-user cohort study assessed Medicare beneficiaries 65 years or older who initiated insulin glargine (n = 407 018), insulin detemir (n = 141 588), or NPH insulin (n = 26 402) from January 1, 2007, to July 31, 2019...In this cohort study, initiation of long-acting analogs was associated with a lower risk of ED visits or hospitalizations for hypoglycemia compared with NPH insulin in older patients with type 2 diabetes in Medicare. However, this association was not seen with concomitant prandial insulin use.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Clinical, Journal: Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. (Pubmed Central) - Jan 12, 2022
The total number of insulin treatment visits declined from a peak of 6.0 million visits in 2016 to a nadir of 4.9 million visits in 2020 (approximately 18% decline). In this study, ambulatory insulin use in the United States during the past 5 years remained dominated by the use of insulin analogs and insulin pen delivery devices, with increasing uptake of newer products as they have been brought to market.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
PK/PD data, Preclinical, Journal: Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir. (Pubmed Central) - Jan 4, 2022
Finally, more superficial injections resulted in faster absorption, higher C/dose and bioavailability of insulin aspart (p<0.05, 3.0 vs. 5.0 mm injection depth). In conclusion, pig breed and injection region affected the PK of liraglutide, insulin aspart and insulin detemir and reliable predictions of human PK were demonstrated when applying single-species allometric scaling with the pig as a pre-clinical animal model.
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Retrospective data, Journal: Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study. (Pubmed Central) - Dec 7, 2021
ACHIEVE Control, a prospective, open-label, randomized, pragmatic, real-life study in insulin-naive people with type 2 diabetes (A1C 8.0-11.0%), demonstrated superiority of insulin glargine 300 units/mL (Gla-300) versus first-generation standard-of-care basal insulin (SOC-BI; glargine 100 units/mL or insulin detemir) in achieving individualized A1C targets without documented symptomatic (glucose ≤3.9 mmol/L [≤70 mg/dL] or <3.0 mmol/L [<54 mg/dL]) or severe hypoglycemia (American Diabetes Association level 3) at 6 months...The results suggest that, in insulin-naive people with type 2 diabetes, Gla-300 is effective with a risk of hypoglycemia that is lower than or similar to that of SOC-BI regardless of background medication. Individuals receiving concomitant sulfonylureas were more likely to remain without symptomatic or severe hypoglycemia with Gla-300.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Clinical, Review, Journal: Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. (Pubmed Central) - Dec 2, 2021
If warranted, switching between basal insulins can be done using simple regimens.The dose of basal insulin should be increased as required up to approximately 0.5-1.0 units/kg/day in some cases. Overbasalization (continuing to escalate dose without a meaningful reduction in fasting plasma glucose) is not recommended; rather re-evaluation of individual therapy, including consideration of more concentrated basal insulin preparations and/or short-acting prandial insulin as well as other glucose-lowering therapies, is suggested.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Selective CNS Targeting and Distribution with a Refined Region-Specific Intranasal Delivery Technique via the Olfactory Mucosa. (Pubmed Central) - Nov 29, 2021
This study successfully demonstrated region-specific administration at the olfactory mucosa resulting in over 20% of the administered fluorescein dose in the olfactory bulbs, and no peripheral bioactivity of insulin detemir and Fc-dependent uptake of two murine IgG1 (11C7 and P3X) along the olfactory pathway to cortex and hippocampus...In summary, it was successfully demonstrated that region-specific intranasal administration via the olfactory region resulted in improved brain targeting and reduced peripheral targeting in mice. The data are discussed with regard to their clinical potential.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P2 trial: DETERMINE: Detemir vs NPH (clinicaltrials.gov) - Nov 18, 2021
P2, N=336, Not yet recruiting,
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Journal: Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update. (Pubmed Central) - Nov 4, 2021
Insulin degludec reduces hypoglycemia risk compared to insulin glargine U100. Future studies should explore the potential for further improvement of treatment results in type 1 diabetes by a structured approach to personalization of basal insulin therapy.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Journal: Facile synthesis of insulin fusion derivatives through sortase A ligation. (Pubmed Central) - Oct 1, 2021
We further demonstrated that a new insulin derivative synthesized by this SrtA-mediated ligation shows strong cellular and in vivo bioactivity. This enzymatic method can therefore be used for future insulin design and development.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
[VIRTUAL] How did we get here? An overview of therapeutic insulin over the past 100 years (Channel 1) - Sep 30, 2021 - Abstract #IDF2021IDF_11;
The future lies with regenerative medicine with the use of islet cells from different sources or in combination including: production of islet B-cells from embryonic stem cells, multiplication of islet B-cells from harvested islet B-cells or induced from pancreatic duct cells, use of donor pancreas, with enhanced multiplication and growth of islet B-cells; use of animal derived islet B-cells, with enhanced multiplication and growth, and antigenic modification; provision of islet B-cell cultures in partially permeable pouches. Learning Objectives 1) Understand the scientific build up to the discovery of insulin 2) Describe the evolution of therapeutic insulin 3) Recognize the future development of therapeutic insulin
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment open, Combination therapy: Afrezza (clinicaltrials.gov) - Sep 21, 2021
P3, N=264, Recruiting,
Current use of long-acting insulin analogs is not associated with a reduced risk of MACE compared to use of NPH insulin among patients with type 2 diabetes. Not yet recruiting --> Recruiting
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion date, Trial primary completion date: CF-IDEA: Cystic Fibrosis - Insulin Deficiency, Early Action (clinicaltrials.gov) - Sep 16, 2021
P3, N=100, Recruiting,
Not yet recruiting --> Recruiting Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Dec 2020 --> Dec 2022
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion date, Trial primary completion date: IDIOM: Insulin Detemir in Obesity Management (clinicaltrials.gov) - Sep 9, 2021
P=N/A, N=240, Active, not recruiting,
The method was applied to13 forensic cases in which insulin use was suspected. Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion date, Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Aug 23, 2021
P3, N=264, Not yet recruiting,
Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022 Trial completion date: Apr 2025 --> Apr 2024 | Trial primary completion date: Apr 2024 --> Apr 2023
- |||||||||| Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal: Predictors of Self-Efficacy in Administering Insulin Injection. (Pubmed Central) - Aug 20, 2021
The findings indicated that "knowledge of diabetes and insulin injection," "insulin injection skills," "senior high school or above education," and "diabetes duration" were predictors of self-efficacy in administering insulin injection, which explained 41% of the total variance in self-efficacy. Health care professionals can design relevant strategies for improving patient self-efficacy in administering insulin injection, thereby increasing patients' insulin self-injection abilities.
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Clinical, Review, Journal: Recent updates in the Alzheimer's disease etiopathology and possible treatment approaches: a narrative review of current clinical trials. (Pubmed Central) - Aug 15, 2021
It is predicted that some FDA-approved drugs such as Paracetamol, Risperidone, Escitalopram, Simvastatin, Cilostazoand, and Ritalin-SR could also use in off-label ways for AD. This review improves our ability to recognize novel treatments for AD and suggesting approaches for the clinical trial design for this devastating disease in the near future.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk
Clinical, Review, Journal, Real-world evidence: Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: a review of the DELIVER programme. (Pubmed Central) - Aug 8, 2021
Evidence from randomized controlled trials (RCTs) has shown that second-generation basal insulin (BI) analogues, insulin glargine 300 U/mL (Gla-300) and insulin degludec (IDeg), provide similar glycaemic control, with a lower risk of hypoglycaemia compared with the first-generation BI analogue insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes (T2D)...Overall, Gla-300 provided similar antihyperglycaemic effectiveness and a lower risk of hypoglycaemia versus the first-generation BI analogues Gla-100 and insulin detemir in people with T2D who had switched BIs...In addition, the DELIVER 2 study reported that people with T2D who switched to Gla-300 had reduced healthcare resource utilisation, with an overall saving of US$1439 per-person per-year, compared with those who switched to another BI analogue. Overall, the real-world DELIVER programme demonstrated that the glycaemic control with low risk of hypoglycaemia observed with Gla-300 in RCTs was also seen in standard clinical practice.
- |||||||||| Xolair (omalizumab) / Roche, Novartis
Clinical, Journal: The complexities of insulin allergy: a case and approach. (Pubmed Central) - Jul 31, 2021
Therapeutic strategies include avoidance and insulin alternatives, alternate insulin preparations, or desensitization. In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal: Financial advantage or barrier when deprescribing for seniors: A case based analysis. (Pubmed Central) - Jul 30, 2021
The scenarios demonstrated a small impact on the pharmacy's gross margin, in some cases a significant financial impact on patient costs, but minimal impact to government. Deprescribing initiatives and policies should include financial considerations for pharmacies and patients.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical, Journal, HEOR: Detemir versus Neutral Protamine Hagedorn Insulin for Diabetes Mellitus in Pregnancy: A Comparative-Effectiveness, Randomized Controlled Trial. (Pubmed Central) - Jul 24, 2021
P4
Bayesian analysis indicated an 87% posterior probability of reduced primary outcome with insulin detemir relative to NPH (posterior adjusted relative risk, 0.88, 95% credible interval, 0.61 - 1.12). Bayesian analyses for secondary outcomes showed consistent findings of lower adverse maternal outcomes with use of insulin detemir vs NPH, e.g. maternal hypoglycemic events (97% probability of benefit, posterior adjusted relative risk 0.59, 95% credible interval, 0.29 - 1.08), and hypertensive disorders (88% probability of benefit, posterior adjusted relative risk 0.81, 95% credible interval 0.54 - 1.16) In our comparative effectiveness trial involving individuals with type 2 diabetes or overt type 2, use of insulin detemir compared to NPH resulted in lower rates of adverse neonatal and maternal outcomes.
|
